Revenue

The European FinTech giant plans a new €70M note issue and a tender offer to refinance debt, signaling a major push for financial flexibility and expansion.

A new line of ultra-pure proteins with endotoxin levels 10x below the standard could revolutionize advanced therapies and fix a key source of error in science.

Despite softer profits and trade tensions, a new report shows US firms plan billions in reinvestment, with Guangzhou leading as the top investment hub.

For the fourth straight year, EPAM is named a top IT vendor in the Netherlands, driven by exceptional client satisfaction and a strategic focus on AI.

Struggling with inconsistent income? A new wave of business strategy uses hard data to build predictable client systems, leaving 'hustle culture' behind.

In just four months, digital asset platform Sambaex has captured a million users in Brazil, signaling a new era for crypto adoption in Latin America.

DevRev expands its AI platform in India, aiming to move enterprise AI from pilot to production and solve the 'clarity crisis' with new agent tools.

As California's commercial property market falters, investment firm Azzet plans a major buying spree, leveraging its digital platform to acquire distressed assets.

With $11.8M in fresh capital, Axiom Trust is emerging from stealth to modernize the archaic trust administration industry ahead of a massive wealth shift.

Telehealth firm Direct Meds offers cheap GLP-1 drugs, but an FDA warning for "false claims" and the end of drug shortages cast a long shadow on its model.

A new report projects the telehealth market will skyrocket to over $2 trillion by 2034, signaling a seismic shift in how we receive medical care.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

As Cal-Maine preps its Q3 report, investors watch if its pivot to prepared foods and specialty eggs can offset plunging prices and new avian flu threats.

With billions in government and private backing, USA Rare Earth hires legal, policy, and finance heavyweights to challenge China's grip on critical minerals.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

With its finances on a knife's edge, Faraday Future is pitching a bold new vision of AI robots and mass-market EVs to skeptical investors. Can it deliver?

A White House-backed program is fast-tracking electric air taxis, with Joby Aviation set to begin early operations across the U.S. in 2026.

Most firms are stuck in AI experiments. A new summit with leaders from Tesla and top banks aims to show ANZ businesses how to get real-world results.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

Transcat appoints decorated industrial leader Jaime Irick as its new CEO, signaling a strategic pivot toward accelerated growth and market expansion.